Results for neuromuscular disease (2)

  News   Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy
Biogen Idec and Isis Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide option and collaboration agreement under which the companies will develop and commercialize Isis’ antisense investigational drug, ISIS-SMNRx, for the treatment of spinal muscular atrophy (SMA).
  News   GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
GlaxoSmithKline (GSK) and Prosensa announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968 (`968), in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with DMD). Commencement of this study confirms previously announced plans to progress this asset into Phase III.

General Search


 Latest News

U.S. Food And Drug Administration Approves Pfizer’s INLYTA (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Pfizer Announces FDA Acceptance Of New Drug Application For Bosutinib For Patients With Previously Treated Ph Chronic Myeloid Leukemia
FDA approves Inlyta to treat patients with a type of advanced kidney cancer
FDA Drug Safety Communication: New risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab)
FDA. New and Generic Drug Approvals - January 27, 2012

 Latest Drugs

Efavirenz Teva
Desloratadine Actavis
Repaglinide Accord
Emselex
Hepsera
Zulvac 1 Ovis
Zulvac 1 Bovis
Levetiracetam Sun
Inovelon
Olanzapine Glenmark Europe

 Latest Articles

Wrist Injuries and Disorders
Valley Fever
Verruca ( Warts)
Von Hippel-Lindau Disease
Vitiligo

Last medical tags:


Torisel, temsirolimus, Inlyta, chronic myeloid leukemia, bosutinib, Inlyta, renal cell carcinoma, kidney cancer, myelin, Tysabri, natalizumab, brain infection, progressive multifocal leukoencephalopathy, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, thoracic aortic transection, endovascular graft, methotrexate, Voraxaze, cancer chemotherapy drug, glucarpidase, Adcetris, bleomycin, multifocal leukoencephalopathy, CardioGen-82, radiation, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, FDA, New drugs approval 2012, drugs approved by FDA, raltegravir, Isentress, antiretroviral medicines, Theravance, Relovair, asthma, fluticasone, bronchitis, neuromuscular disease, SMA, muscle atrophy, Resolor, prokinetic, prucalopride, ADHD, psychiatric behavioural disorder, Venvanse, lisdexamfetamine dimesylate, type 2 diabetes mellitus, Actoplus Met XR, pioglitazone, Mylan, Eprosartan Mesylate Tablets, Teveten, antimicrobials, cephapirin, cephalosporin, teriflunomide, Rebif, alanine aminotransferase levels, flu-like symptoms, multiple sclerosis, electrical pulses, implantable pulse generator, Precision Plus Spinal Cord Stimulator, genetic blood clotting disorder, hemophilia A, Advate, bleeding episodes, heart failure, heart transplantation, Pediatric Medical Device Safety, pulsatile cardiac assist device, selective serotonin reuptake inhibitor, SSRI, pulmonary hypertension,
» All tags  
Sitemap